Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. - Wikidata - awgldk - TriplyDB

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

http://www.wikidata.org/entity/Q33804845

about

New viruses for cancer therapy: meeting clinical needs Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 Intelligent design: combination therapy with oncolytic viruses The status of gene therapy for brain tumors Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis Inhibitors of C5 complement enhance vaccinia virus oncolysis.Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses Impact of tumor microenvironment on oncolytic viral therapy VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review.Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.Classification of current anticancer immunotherapies Design and application of oncolytic HSV vectors for glioblastoma therapy.Oncolytic herpes viruses as a potential mechanism for cancer therapy.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.Herpes simplex virus 1 (HSV-1) for cancer treatment.Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Trial watch: Oncolytic viruses for cancer therapy Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Gene therapy: the end of the rainbow?Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Oncolytic viruses: a novel form of immunotherapy.Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

P2860

Q24567699-A8E347E0-006E-4C95-AD04-457946BA0463 Q24596171-A08BECF1-473D-4B7E-868F-097E750A3F2D Q24612603-A67328A5-0093-4EFE-81CB-69394586C128 Q24628227-C6C31DE4-AB2E-4D31-A85C-1E57A9280BD1 Q24651009-6A3B57ED-6FB6-4803-BD17-C174500BE019 Q26769977-2A783317-7C86-41DB-A77E-71E3DE7C99A6 Q26863779-748F6AC0-6E4D-4B0C-A7A2-C7D431A6CD0E Q27021839-B1DC1E77-E1FF-4F80-ABC9-5AA69D00360D Q27021951-2123A315-682E-44F4-A1C2-373EEB186350 Q28072347-5BF9595B-6078-49C7-9010-482D894B627C Q33641230-8D2CA6E5-7380-4F67-9049-67448EE4ACB0 Q33675567-B26173B4-09AB-4199-8EF2-929FA67CB28F Q33768177-147B6AB1-BF20-4A53-B52E-078888E4DAEB Q33773376-EA1E5E8C-9469-4DDE-8AF8-D00D702EA154 Q33895533-A635B9FE-BBA2-42D4-8ABD-3569C0F17F35 Q33976318-437F2262-D969-4E9C-BCB9-C2604BFE1FEE Q33985663-9662D9DC-DD3B-4468-BAEC-D206A4D996F6 Q34335296-126BE356-FDCE-4B86-8A03-B4842768368A Q35036505-51B08103-E8D4-4B4F-909E-433F44BDE7C8 Q35116166-ED0E0A10-CD7F-4169-B476-A5FB2713ED2C Q35126267-A0355E03-061E-4E5E-883D-AE16F76E874D Q35131235-A1FB4900-1FF0-43BB-9478-110C5850FDE6 Q35149637-63E029E3-16C8-48E2-9B46-5E4EF6012651 Q35559877-E7A6324B-28BA-435B-9939-185F8621A6DB Q35613495-801294B5-9844-432D-88A6-7963A01C076A Q35687743-8BB8A8EF-EA51-4252-A4D5-63D5C7141814 Q36109704-043DBAEC-BA6E-43DD-B2B0-7E9040444F3C Q36221386-E8CA4FAA-09AE-4BF1-8921-A3A61021ADDC Q36298634-B54CEB5D-2ED9-40C1-BC73-E23BF6B62BDE Q36444443-495F0745-D094-4022-B7CC-AD6743BA178E Q36756690-DA96F312-046B-4E45-8E52-42B089D55A60 Q36967306-62906644-970A-434D-BA19-CA83F5DCF3E6 Q37010979-FCABEE25-8FE9-41DC-AFFD-180B7B3EE473 Q37028023-76F0CF81-EEA1-4CBD-A354-88D042AF8E8C Q37138701-9715FEB0-01F3-4F0A-981D-26531368B0CB Q37158473-EC2C0AAF-CE5D-4F30-8D99-3E7563E59492 Q37158534-AB33414D-D458-445F-946F-BC38C0F31791 Q37256174-8CB3FAA7-532F-4F41-80D5-A069BA052E04 Q37300008-599DB18A-66B9-4166-A852-D609EA9988EF Q37311960-D0BF05C5-4C0E-4FBD-9B96-DC6123E3F770

P2860

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

http://www.wikidata.org/entity/Q33804845

description

2000 nî lūn-bûn

@nan

2000 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Complement depletion facilitat ...... l herpes simplex virus mutant.

@ast

Complement depletion facilitat ...... l herpes simplex virus mutant.

@en

type

label

Complement depletion facilitat ...... l herpes simplex virus mutant.

@ast

Complement depletion facilitat ...... l herpes simplex virus mutant.

@en

prefLabel

Complement depletion facilitat ...... l herpes simplex virus mutant.

@ast

Complement depletion facilitat ...... l herpes simplex virus mutant.

@en

P1433

Q33804845-FA3A103F-13C0-4DF9-953D-E1BF01FF1515

P1476

Q33804845-7EE2B5E0-3C46-4ABF-9665-6D93B8D78DE6

P2093

Q33804845-18C6EA1B-7727-4BA2-8C7B-8C72359B5A8B

Q33804845-1B05B3E4-A5B7-4E22-91FC-53DEC337DABF

Q33804845-3AC8793A-A706-4D48-A501-5E14210754F5

Q33804845-3D751A7A-B355-4F3A-BD65-25DB46B5DABC

Q33804845-4CC7D4AD-D070-4034-A252-3AD128BEF874

Q33804845-53082678-1FF6-4D5B-AA04-EF004A376440

Q33804845-EDAD5A4C-8E16-4067-9DAA-4EDC958378B7

P2860

Q33804845-0601C8C5-D037-4DA0-A71A-E29BCDF180EB

Q33804845-06C428D3-A4C5-4714-BA64-20014C0B115F

Q33804845-09F47A46-FA90-436A-8581-7FBD0E5DD7A2

Q33804845-0B844A9F-4832-44A2-9528-D70BDF67B991

Q33804845-113975C1-D92D-4E58-A5ED-A9FCEB78E439

Q33804845-1CA58C49-0069-45C4-B59C-527E2F85843F

Q33804845-1CF7E58D-B7EB-41EF-88FE-65E03A88A678

Q33804845-30F56008-31DC-4DE2-A978-88D0D6668849

Q33804845-33B30AE4-4007-46A5-AD5E-E10A7C68A22C

Q33804845-34505CBA-64EA-4925-90FC-E51D0D2E5F3F

P304

Q33804845-D461F130-3AB2-4D37-A72C-0A2ACE709E3B

P31

Q33804845-C1D5FB80-BC5D-4B92-99FB-828FBC33B35F

P356

Q33804845-E08E5F8D-1AFC-48A0-90D3-FA783FB1BE7E

P433

Q33804845-2AA5282E-6411-4DC0-8F4E-8ED4DDAB6B17

P478

Q33804845-D5867C62-CA3A-4BCC-BA3C-C32240D7E899

P577

Q33804845-9D3EA39F-7135-48F7-BB16-101E14AE7FDB

P698

Q33804845-ECB0B4E7-D512-4310-A5DD-960874B29F03

P932

Q33804845-C0A17F7A-65D3-4763-8531-93CB8E656F36

P356

JVI.74.10.4765-4775.2000

P1433

Journal of Virology

P1476

Complement depletion facilitat ...... l herpes simplex virus mutant.

@en

P2093

D N Louis

http://www.w3.org/2001/XMLSchema#string

E A Chiocca

http://www.w3.org/2001/XMLSchema#string

F H Hochberg

http://www.w3.org/2001/XMLSchema#string

H Wakimoto

http://www.w3.org/2001/XMLSchema#string

K Ikeda

http://www.w3.org/2001/XMLSchema#string

S Jhung

http://www.w3.org/2001/XMLSchema#string

T Ichikawa

http://www.w3.org/2001/XMLSchema#string

P2860

Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity

Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo

Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.

Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system.

P304

4765-4775

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.74.10.4765-4775.2000

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2000-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10775615

http://www.w3.org/2001/XMLSchema#string

P932

111999

http://www.w3.org/2001/XMLSchema#string